Using disease registries for pharmacoepidemiological research: A case study of data from a cystic fibrosis registry

Pharmacoepidemiology and Drug Safety

Volumn 12, Issue 6, 2003, Pages 467-473

  Strobl, Judith ^a   Enzer, Ian ^a   Bagust, Adrian ^a   Haycox, Alan ^a   Smyth, Rosalind ^a   Ashby, Deborah ^b   Walley, Tom ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cystic fibrosis; Data verification; Disease registry

Indexed keywords

DORNASE ALFA;

ACCURACY; ANALYSIS OF VARIANCE; ARTICLE; CASE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DATA ANALYSIS; DISEASE EXACERBATION; HUMAN; INFORMATION PROCESSING; LUNG DISEASE; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; QUALITY CONTROL; REGISTER; RELIABILITY; UNITED KINGDOM;

ADULT; CHILD; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; FEMALE; HUMANS; MALE; REGISTRIES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0042413918     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.804     Document Type: Article

References (18)

1. Wood L, Coulson R. Revitalising the general practice research database: plans, challenges, and opportunities. Pharmacoepidemiol Drug Safe 2001; 10: 379-383.
2. Downey W, Beck P, McNutt M, Stang MR, Osei W, Nichol J. Health databases in Saskatchewan. In Pharmacoepidemiology (3rd edn). Strom BL (ed.). Wiley: Chichester, 2000; 325-345.
3. Ledergerber B, Overbeck J, Egger M, Lüthy R, Swiss HIV Cohort Study (SHCS). The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Präventivmed 1994; 39: 387-394.
4. Proctor S, Taylor P. A practical guide to continuous population-based data collection (PACE): a process facilitating uniformity of care and research into practice. Q J Med 2000; 93: 67-73.
5. Glover G. A comprehensive clinical database for mental health care in England. Soc Psychiatry Psychiatr Epidemiol 2000; 35: 523-529.
6. Singh G. Arthritis, rheumatism and aging medical information system post-marketing surveillance program. J Reumatol 2001; 28: 1174-1179.
7. Elphick H, Tan A, Ashby D, Smyth R. Systematic reviews and life-long diseases. BMJ 2002; 325: 381-384.
8. Sørensen H, Sabroe S, Olsen J. A framework for evaluation of secondary data sources for epidemiological research. Int J Epidemiol 1996; 25: 435-442.
9. Kearney CE, Wallis CE. Deoxyribonuclease for cystic fibrosis (Cochrane Review). In The Cochrane Library, Issue 3, 2001. Update Software: Oxford.
10. Quan J, Tiddens A, Sy J, et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001; 139: 813-820.
11. Rabeneck L, Menke T, Simberkoff M, et al. Using the national registry of HIV-infected veterans in research: lessons for the development of disease registries. J Clin Epidemiol 2001; 54: 1195-1203.
12. Hughes D, Bagust A, Haycox A, Walley T. Accounting for noncompliance in pharmacoeconomic evaluations. Pharmacoeconomics 2001; 19: 1185-1197.
13. Phillips J, Bunting J, Masel P, Bell S. Pulmozyme adherence in an adult cystic fibrosis unit. Pediatr Pulmonol 2001; Suppl. 22: A407.
14. Dodd M, Haworth C, Webb A, Talbot S. The medical and economic consequences of non-compliance in clinical trials and in primary care. Thorax 1998; 53: A18.
15. Schulman K, Yabroff K, Kong J, et al. A claims data approach to defining an episode of care. Pharmacoepidemiol Drug Safe 2001; 10: 417-427.
16. Koch C, McKenzie S, Kaplowitz H, et al. International practice patterns by age and severity of lung disease in cystic fibrosis: data from the Epidemiologic Registry of Cystic Fibrosis (ERCF). Pediatr Pulmonol 1997; 24: 147-154; discussion 159-161.
17. Strobl J, Cave E, Walley T. Data protection legislation: interpretation and barriers to research. BMJ 2000; 321: 890-892.
18. Strom B. Data validity issues in using claims data. Pharmacoepidemiol Drug Safe 2001; 10: 389-392.